Publications en collaboration avec des chercheurs de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (67)

2024

  1. Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human

    Vascular Pharmacology, Vol. 155

  2. Editorial: Therapeutics in pulmonary arterial hypertension

    Frontiers in Cardiovascular Medicine

  3. Role of KCNK3 Dysfunction in Dasatinib-associated Pulmonary Arterial Hypertension and Endothelial Cell Dysfunction

    American journal of respiratory cell and molecular biology, Vol. 71, Núm. 1, pp. 95-109

  4. Vitamin D and Pulmonary Arterial Hypertension

    Archivos de Bronconeumologia

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Dietary Supplementation with a Cocoa–Carob Blend Modulates Gut Microbiota and Prevents Intestinal Oxidative Stress and Barrier Dysfunction in Zucker Diabetic Rats

    Antioxidants, Vol. 12, Núm. 8

  3. Glycolysis in pulmonary arterial hypertension and metabolic reprogramming

    Glycolysis: Tissue-Specific Metabolic Regulation in Physio-pathological Conditions (Elsevier), pp. 267-296

  4. Hydrogen sulfide regulates the redox state of soluble guanylate cyclase in CSE-/- mice corpus cavernosum microcirculation

    Pharmacological Research, Vol. 194

  5. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  6. Oxidized soluble guanylyl cyclase causes erectile dysfunction in alcoholic mice

    British Journal of Pharmacology, Vol. 180, Núm. 18, pp. 2361-2376

  7. Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart

    Journal of Physiology, Vol. 601, Núm. 17, pp. 3717-3737

  8. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063

  9. Sigma-1 receptor modulation fine-tunes KV1.5 channels and impacts pulmonary vascular function

    Pharmacological Research, Vol. 189

  10. Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension

    Frontiers in Pharmacology, Vol. 14

  11. Targeting IL-11 system as a treatment of pulmonary arterial hypertension

    Pharmacological research, Vol. 197, pp. 106985

  12. The novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit

    Biomedicine and Pharmacotherapy, Vol. 164

  13. Vitamin D Receptor Deficiency Upregulates Pulmonary Artery Kv7 Channel Activity

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. Antiproliferative miR-212-5p: Promising RNA therapy for pulmonary hypertension

    Molecular Therapy - Nucleic Acids

  2. Cardiac and Pulmonary Vascular Dysfunction in Vitamin D-Deficient Bmpr2-Mutant Rats

    American journal of respiratory cell and molecular biology

  3. Supplementation with a Cocoa–Carob Blend, Alone or in Combination with Metformin, Attenuates Diabetic Cardiomyopathy, Cardiac Oxidative Stress and Inflammation in Zucker Diabetic Rats

    Antioxidants, Vol. 11, Núm. 2